INTEGRAL DIAGNOSTICS LIMITED (IDX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IDX

IDX - INTEGRAL DIAGNOSTICS LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 5.14
Index: ASX300 | ALL-ORDS

Integral Diagnostics is an Australian healthcare services company providing diagnostic imaging services to medical practitioners in Australia and New Zealand. It has been a listed company since 2015.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.91

29 Aug
2025

-0.030

OPEN

$2.91

-1.02%

HIGH

$2.97

1,974,840

LOW

$2.88

TARGET
$3.35 15.1% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . DOC . EBO . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
IDX: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 1.5 13.2 xxx
DPS (cps) xxx 6.5 8.7 xxx
EPS Growth xxx N/A 100.0% xxx
DPS Growth xxx 12.1% 33.1% xxx
PE Ratio xxx N/A 22.0 xxx
Dividend Yield xxx N/A 3.0% xxx
Div Pay Ratio(%) xxx 427.6% 65.4% xxx

Dividend yield today if purchased 3 years ago: 2.25%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 2.23

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 29/02 - ex-div 2.5c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx1.5
DPS All xxxxxxxxxxxxxxx6.5
Sales/Revenue xxxxxxxxxxxxxxx627.2 M
Book Value Per Share xxxxxxxxxxxxxxx186.2
Net Operating Cash Flow xxxxxxxxxxxxxxx73.8 M
Net Profit Margin xxxxxxxxxxxxxxx0.75 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx0.94 %
Return on Invested Capital xxxxxxxxxxxxxxx0.49 %
Return on Assets xxxxxxxxxxxxxxx0.43 %
Return on Equity xxxxxxxxxxxxxxx0.94 %
Return on Total Capital xxxxxxxxxxxxxxx5.90 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-1.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx20 M
Long Term Debt xxxxxxxxxxxxxxx565 M
Total Debt xxxxxxxxxxxxxxx585 M
Goodwill - Gross xxxxxxxxxxxxxxx802 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx52 M
Price To Book Value xxxxxxxxxxxxxxx1.36

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx59.8 M
Capex % of Sales xxxxxxxxxxxxxxx9.53 %
Cost of Goods Sold xxxxxxxxxxxxxxx489 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx82 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

27/08/2025

1

Buy

$3.30

13.40%

Integral Diagnostics announced a slight 1% earnings (EBITDA) beat against Ord Minnett and consensus forecasts.

Australian market share rose in 2H25 after underperforming in FY24–1H25, the analyst highlights. The 2H25 group earnings (EBITDA) margin rose 110bps to 21.4%.

The FY26 outlook remains positive, with like-for-like sales for July revenue growth of 7% on the prior year and an updated synergy target for Capitol of $14m versus $10m previously.

Target price rises to $3.30 from $3.00. No change in Buy rating. Ord Minnett lowers its FY26 EPS forecast by -3% and raises FY27 by 2%.

FORECAST
Ord Minnett forecasts a full year FY26 dividend of 9.00 cents and EPS of 12.60 cents.
Ord Minnett forecasts a full year FY27 dividend of 10.60 cents and EPS of 15.10 cents.

Citi

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

3

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

05/05/2025

1

Buy

$3.45

18.56%

Jarden believes Integral Diagnostics is facing challenges in 2H25 and, after re-assessing this business and the merged Capitol Health, the broker downgraded FY25 group EBITDA margins by -20bps.

The broker cut 2H25 revenue forecast to reflect the impact of Easter/Anzac Day holiday timings, and in the case of Integral, the Cyclone Alfred impact and staffing pressures in regional Victoria. Capitol's revenue is expected to suffer from competitive pressure in metro Victoria.

FY26 is expected to see a rebound, with the broker's EBITDA forecast sitting 8% ahead of consensus.

Buy. Target cut to $3.45 from $3.51.

FORECAST
Jarden forecasts a full year FY26 dividend of 7.00 cents and EPS of 15.30 cents.

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Extra Coverage Research History >

IDX STOCK CHART

FNArena News on IDX

1
FNArena Corporate Results Monitor – 27-08-2025

Aug 27 2025 - Australia
2
Rudi’s View: BlueScope Steel, IGO, GrainCorp, Pilbara Minerals, Santos & More

Aug 14 2025 - Rudi's View
3
Rudi’s View: AI Updates, Hot Favourites & First August Results

Aug 07 2025 - Rudi's View
4
Rudi’s View: Bega Cheese, Cettire, Harvey Norman, Sigma, SiteMinder & More

Jul 24 2025 - Rudi's View
5
Rudi’s View: Aussie Broadband, oOh!media, Paladin Energy, Seek, Xero & More

Jul 17 2025 - Rudi's View

Latest Healthcare services News

1
Better Times Ahead For Sonic Healthcare?

Jun 20 2025 - Australia
2
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
3
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
4
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
5
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
6
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
7
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
8
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
9
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
10
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps